Teladoc, Inc. (NYSE:TDOC) – Research analysts at Oppenheimer Holdings raised their Q4 2018 EPS estimates for shares of Teladoc in a research report issued on Tuesday. Oppenheimer Holdings analyst M. Naidu now expects that the health services provider will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.16). Oppenheimer Holdings has a “Outperform” rating and a $45.00 price target on the stock. Oppenheimer Holdings also issued estimates for Teladoc’s Q1 2019 earnings at ($0.20) EPS, Q2 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.14) EPS and FY2019 earnings at ($0.58) EPS.

Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.25). The firm had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The company’s quarterly revenue was up 112.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.33) EPS.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/23/oppenheimer-holdings-weighs-in-on-teladoc-inc-s-q4-2018-earnings-tdoc.html.

TDOC has been the subject of several other research reports. Cantor Fitzgerald reissued a “hold” rating on shares of Teladoc in a research note on Monday, August 28th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $40.00 target price on shares of Teladoc in a research note on Friday, November 3rd. BidaskClub raised shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Zacks Investment Research downgraded shares of Teladoc from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $42.00 price target on shares of Teladoc in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $39.00.

Teladoc (NYSE TDOC) traded up $0.40 during trading hours on Thursday, hitting $34.00. The stock had a trading volume of 1,039,700 shares, compared to its average volume of 933,844. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08. Teladoc has a fifty-two week low of $15.65 and a fifty-two week high of $37.55.

Several hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in shares of Teladoc by 1.3% during the 2nd quarter. FMR LLC now owns 8,209,737 shares of the health services provider’s stock valued at $284,879,000 after acquiring an additional 106,500 shares in the last quarter. BlackRock Inc. raised its position in shares of Teladoc by 42.9% during the 2nd quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after acquiring an additional 1,154,852 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Teladoc by 24.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,313,729 shares of the health services provider’s stock valued at $108,193,000 after acquiring an additional 650,129 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Teladoc by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock valued at $105,547,000 after acquiring an additional 314,646 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Teladoc by 22.2% during the 2nd quarter. Alliancebernstein L.P. now owns 2,793,590 shares of the health services provider’s stock valued at $96,938,000 after acquiring an additional 507,390 shares in the last quarter.

In related news, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.10, for a total transaction of $642,000.00. Following the sale, the chief executive officer now directly owns 838,261 shares of the company’s stock, valued at approximately $26,908,178.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Mark Hirschhorn sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $31.93, for a total value of $798,250.00. Following the sale, the vice president now directly owns 64,987 shares in the company, valued at $2,075,034.91. The disclosure for this sale can be found here. Insiders have sold a total of 135,000 shares of company stock worth $4,408,700 over the last three months. 4.47% of the stock is currently owned by corporate insiders.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.